BrightGene Bio Medical Technology C (688166) — Working Capital to Net Assets Ratio
BrightGene Bio Medical Technology C (688166) has a Working Capital to Net Assets ratio of 15.0% as of June 2025. Working capital of CN¥386.93 Million (current assets of CN¥1.54 Billion minus current liabilities of CN¥1.16 Billion) is measured against net assets of CN¥2.59 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See BrightGene Bio Medical Technology C (688166) balance sheet quality index to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
BrightGene Bio Medical Technology C Working Capital to Net Assets (2016–2024)
This chart shows how BrightGene Bio Medical Technology C's Working Capital to Net Assets ratio has evolved across 9 annual periods from 2016 to 2024. As of June 2025, the ratio stands at 15.0%, reflecting working capital of CN¥386.93 Million against net assets of CN¥2.59 Billion CNY. Check BrightGene Bio Medical Technology C (688166) tangible net worth to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for BrightGene Bio Medical Technology C (2016–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for BrightGene Bio Medical Technology C from 2016 to 2024, covering 9 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see 688166 stock market capitalisation.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 24.1% | CN¥587.89 Million | CN¥2.44 Billion | CN¥1.64 Billion | CN¥1.05 Billion | ▼ -13.8 pp |
| 2023 | 38.0% | CN¥917.49 Million | CN¥2.42 Billion | CN¥1.84 Billion | CN¥922.25 Million | ▼ -12.3 pp |
| 2022 | 50.3% | CN¥1.13 Billion | CN¥2.24 Billion | CN¥1.94 Billion | CN¥811.52 Million | ▲ +26.7 pp |
| 2021 | 23.5% | CN¥409.94 Million | CN¥1.74 Billion | CN¥993.01 Million | CN¥583.07 Million | ▼ -22.2 pp |
| 2020 | 45.7% | CN¥654.65 Million | CN¥1.43 Billion | CN¥946.36 Million | CN¥291.71 Million | ▼ -26.9 pp |
| 2019 | 72.6% | CN¥953.83 Million | CN¥1.31 Billion | CN¥1.06 Billion | CN¥108.21 Million | ▲ +13.5 pp |
| 2018 | 59.2% | CN¥457.29 Million | CN¥772.85 Million | CN¥562.81 Million | CN¥105.52 Million | ▲ +9.6 pp |
| 2017 | 49.5% | CN¥220.87 Million | CN¥446.02 Million | CN¥299.77 Million | CN¥78.89 Million | ▲ +29.0 pp |
| 2016 | 20.5% | CN¥45.11 Million | CN¥220.15 Million | CN¥209.15 Million | CN¥164.05 Million | — |